Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.58 |
| ▸ | HTR3B | O95264 | 4/20 | 0.58 |
| ▸ | HTR3A | P46098 | 4/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | HTR7 | P34969 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27773656 | 0.98 | THRB (0.58) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8787117 | 0.87 | HTR7 (0.54) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL4659980 | 0.86 | ADRB1 (0.62) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Piperazine SCHEMBL28861545 | 0.85 | ADRB1 (0.60) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6260125 | 0.83 | ADRB1 (0.58) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8280092 | 0.81 | ADRB1 (0.60) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8436656 | 0.80 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8440963 | 0.80 | ADRB1 (0.55) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8251013 | 0.79 | ADRB1 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5761993 | 0.77 | ADRB1 (0.64) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109103-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2025-04-03 | — | — | US | disclosed |
| US-12139458-B2 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | UNIWERSYTET JAGIELLONSKI (PL) | 2024-11-12 | — | — | US | disclosed |
| CN-113272292-B | (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases | 雅盖隆大学 | 2024-04-12 | — | — | CN | disclosed |
| US-20220073461-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) | 2022-03-10 | — | — | US | disclosed |
| EP-3908580-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | UNIWERSYTET JAGIELLONSKI (PL) | 2021-11-17 | — | — | EP | disclosed |
| CN-113272292-A | (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases | 雅盖隆大学 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020145831-A1 | (2,5-DIOXOPYRROLIDIN-L-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | Uniwersytet Jagielloński (PL) | 2020-07-16 | — | — | WO | disclosed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-2038268-A2 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007148208-A2 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | ADRB1 46/4885HTR3E 259/4885HTR3B 128/4885 |
| US-20220073461-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | TRPV5, P2RX5, TRPV1 | ADRB1 2444/4885HTR3E 1577/4885HTR3B 1735/4885 |
| US-12139458-B2 | (2,5-dioxopyrrolidin-1-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases | TRPV5, P2RX5, TRPV1 | ADRB1 2444/4885HTR3E 1577/4885HTR3B 1735/4885 |
| US-20250109103-A1 | (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | TRPV5, SCN5A, P2RX5 | ADRB1 2648/4885HTR3E 1775/4885HTR3B 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.